Drug Trial Radar · NCT06905054
Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation
Last checked: Nov 20, 2026Latest source record: Jul 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Apr 15, 2025
Primary completion
Mar 30, 2028
Study completion Jul 1, 2028
Sponsor
- Lead sponsor
- Mayo ClinicAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 1, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to determine the efficacy of 36 months once-daily fenofibrate in preventing clinically-detectable recurrence of primary sclerosing cholangitis after liver transplantation, compared with a historical control cohort that was not treated with
Conditions
- Primary Sclerosing Cholangitis
- Liver Transplant, Complications
- PSC
- Biliary Strictures
Interventions
Fenofibrate (drug)Drug
Once daily fenofibrate for 36 months
Blood draw for the laboratory assessmentDiagnostic test
Serum assessments will be performed every 3 months during the study period
MRI using a hepatobiliary phase contrast agent (Gd-EOB-DPTA)Diagnostic test
Participants will undergo a quantitative gadoxetate-enhanced MRI and MRCP at baseline, and at 12 months and 36 months of trial participation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine the incidence of rPSC in LT recipients treated with fenofibrate, compared with an untreated control cohort.Time frame: 36 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mayo Clinic in Arizona
Scottsdale, Arizona · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.